Skip to main
ALKS
ALKS logo

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Alkermes PLC is positioned for robust revenue growth through 2030, bolstered by the immediate profitability of Lumryz and the anticipated annualized sales of approximately $265-$275 million by 2025, with potential for considerable expansion in subsequent years. The company's strategic investments, particularly in alixorexton's development and ongoing growth initiatives for Aristada and Lybalvi, are expected to enhance earnings per share as it navigates patent expirations and royalty reductions. The successful acquisition of Lumryz not only strengthens Alkermes' commercial capabilities but also aligns with essential growth drivers that support both near-term revenue and long-term financial stability.

Bears say

Alkermes PLC faces a negative outlook primarily due to the projected decline in Lumryz sales beyond 2030, along with the loss of exclusivity in 2037, which is expected to contribute to a stagnating revenue growth trajectory amid increasing competition in the narcolepsy treatment space. The company's reliance on the performance of its orexin program, which is still in early-stage development, poses significant risks, particularly if the efficacy and safety are not established in larger studies. Additionally, potential erosion of its royalty business and the effects of evolving payer dynamics could pressure earnings, further reinforcing the negative perspective on the company's financial stability.

Alkermes (ALKS) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 12 analysts, Alkermes (ALKS) has a Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.